DeepMed Research

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety/Efficacy of Balicatib (AAE581) in Adults With Osteoarthritis of the Knee

Phase 2

Completed

Conditions: Knee Osteoarthritis

First Posted Date: 2006-09-04

Last Posted Date: 2017-03-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 223

Registration Number: NCT00371670

Locations: 🇺🇸
Pinnacle Research Group, Anniston, Alabama, United States
🇩🇪
Novartis, Nuernberg, Germany

Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients

Phase 3

Completed

Conditions: Renal Transplantation

Interventions: Drug: Enteric-coated mycophenolate sodium (EC-MPS)

First Posted Date: 2006-08-29

Last Posted Date: 2011-03-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 128

Registration Number: NCT00369278

Locations: 🇩🇪
Novartis Investigational Site, Various Cities, Germany

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Aliskiren
Drug: Ramipril
Drug: Hydrochlorothiazide
Drug: Amlodipine

First Posted Date: 2006-08-24

Last Posted Date: 2011-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 901

Registration Number: NCT00368277

Locations: 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

Combination Of Lapatinib With Carboplatin, Paclitaxel, and With or Without Trastuzumab In Metastatic Breast Cancer.

Phase 1

Completed

Conditions: Neoplasms, Breast

Interventions: Drug: lapatinib
Drug: carboplatin
Drug: paclitaxel
Drug: trastuzumab

First Posted Date: 2006-08-23

Last Posted Date: 2020-09-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT00367471

Locations: 🇺🇸
Novartis Investigative Site, Greensboro, North Carolina, United States

Safety/Efficacy of Everolimus in Adults With Advanced Pancreatic Neuroendocrine Cancer Not Responsive to Chemotherapy

Phase 2

Completed

Conditions: Islet Cell Carcinoma
Neuroendocrine Carcinoma
Neuroendocrine Tumor
Pancreatic Neoplasms

Interventions: Drug: Everolimus 10 mg
Drug: Octreotide Depot

First Posted Date: 2006-08-15

Last Posted Date: 2013-05-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 160

Registration Number: NCT00363051

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Miami, Miami, Florida, United States
🇺🇸
Scott & White Memorial Hospital, Temple, Texas, United States

and more 18 locations

Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: placebo
Drug: Vildagliptin AM
Drug: vildagliptin pm

First Posted Date: 2006-07-13

Last Posted Date: 2016-11-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 370

Registration Number: NCT00351884

Locations: 🇩🇪
Novartis Investigative Site, Investigative Centers, Germany
🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States

A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2006-07-13

Last Posted Date: 2012-05-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT00351507

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

EXTEND (Eltrombopag Extended Dosing Study)

Phase 3

Completed

Conditions: Purpura, Thrombocytopaenic, Idiopathic

Interventions: Drug: eltrombopag olamine (SB-497115-GR)

First Posted Date: 2006-07-12

Last Posted Date: 2017-04-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 302

Registration Number: NCT00351468

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam
🇹🇳
Novartis investigative Site, Sfax, Tunisia

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate

Phase 3

Completed

Conditions: Autoimmune Disease

Interventions: Drug: Enteric-coated Mycophenolate Sodium

First Posted Date: 2006-07-12

Last Posted Date: 2011-04-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 111

Registration Number: NCT00351377

Locations: 🇩🇪
Novartis Investigational Site, Various cities, Germany

Efficacy of Lumiracoxib in Relieving Moderate to Severe Post-dental Surgery Pain, Compared to Both Placebo and Celecoxib

Phase 4

Completed

Conditions: Pain

First Posted Date: 2006-07-04

Last Posted Date: 2017-02-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 364

Registration Number: NCT00348491

Locations: 🇺🇸
Dental Research Clinic, Austin, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy